We have developed a key laboratory reagent to advance and standardise assessment of antibody responses to Mpox elicited by infection or vaccination, in partnership with the Coalition for Epidemic Preparedness Innovations (CEPI).
The research reagent for Monkeypox virus antibodies is available now and can be ordered from our NIBSC catalogue.
The Mpox antibody reagent has been developed with the aim of harmonising how different laboratories assess the strength and duration of immune responses, such as those generated by current vaccines and those in development against Mpox.
To create the reference reagent, plasma samples from convalescent Mpox donors, who had previously been infected in the Democratic Republic of Congo were collected, assessed and pooled together. The reagent can be used to develop new tests to detect Mpox antibodies and to harmonise the results between different laboratories, contributing to a better assessment of vaccine performance.